As part of a collaboration with Freenome, Institut Curie will look for correlations between circulating biomarkers and human response to cancer immunotherapies.
The latest version of the nucleic acid detection platform uses three CRISPR enzymes, making it more sensitive and capable of smaller quantitative measurements.
The company expects to be able to offer at least one test commercially by the end of this year or early next, with research now starting on two others.
The Ontario Institute of Cancer Research-hosted Cancer Genome Collaboratory has amassed 650 TB of data and supported early discovery of mutations.
The companies will combine Empire's NGS services and FISH probe portfolio with Kromatid's Pinpoint probes and directional genomic hybridization technology.
Syapse has raised new venture capital to support expansion into community hospitals that want to start precision oncology programs.
Promega's technology will be part of a larger portfolio of research products aimed at supporting oncology drug and clinical trial development.
BioSequence is looking to raise the profile of its genomic offering among clinicians, and to strengthen its case for reimbursement.
Spun out of Moffitt Cancer Center, M2Gen and the Total Cancer Care protocols promise rapid advancements in precision medicine, starting with oncology.
The collaborators have signed a two-year research and license option agreement to develop novel T-cell therapies for cancer using genome editing technology.
Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing.
Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.
Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports.
In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.